Feb. 2 at 2:56 PM
$CHRS Remember back in December on the Baird fireside chat when Dr. Daneng Li, one of the principal trial investigators was asked if Casdozo gets approved for frontline HCC, how does he envision treating patients with it, he said "If this an approved triplet regimen compared to our current standard of care, there is no doubt in my mind that the entire oncology community will use it as the de-facto regimen." Thats a
$4 billion dollar statement right there.
